ziprasidone and olanzapine

2020 Feb;270(1):83-94. doi: 10.1007/s00406-019-01063-4. The compliance was checked every visit by counting the unused blisters. Implementing Precision Psychiatry: A Systematic Review of Individualized Prediction Models for Clinical Practice K. P. Grootens, N. M. J. van Veelen, J. Peuskens, B. G. C. Sabbe, E. Thys, J. K. Buitelaar, R. J. Verkes, R. S. Kahn, Ziprasidone Vs Olanzapine in Recent-Onset Schizophrenia and Schizoaffective Disorder: Results of an 8-Week Double-Blind Randomized Controlled Trial, The second-generation antipsychotics (SGAs) have established a prominent role in the treatment of schizophrenia due to better treatment adherence and a lower risk of extrapyramidal side effects.In the present study, we compared the effects of 2 SGAs: olanzapine and ziprasidone. Unable to load your delegates due to an error It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwideFor full access to this pdf, sign in to an existing account, or purchase an annual subscription. We have therefore set out to … The criterion “maintenance over a 6-month period” could not be applied in the present study.All adverse events, regardless of the causal relationship, were monitored and assessed on severity. Weight change ≥ 7% increase of total body weight. However, multiple studies of olanzapine have shown associated isk for weight gain, increased r triglyceride levels and impaired glucose regulation. Patients with marked liver function abnormalities were immediately withdrawn from the study (SGOT/SGPT ≥ 3 × upper limit of the norms, alkaline phosphates ≥ 1.5 × upper limit, total bilirubin ≥ 2 × upper limit). Unable to load your collection due to an error Search for other works by this author on: Kahn has received grants, received honoraria for education programs, or served as consultant for Astellas, AstraZeneca, BMS, Eli Lilly, Janssen-Cilag, Pfizer, Roche, and Sanofi-Aventis.Oxford University Press is a department of the University of Oxford. Sabbe has been a member of advisory board or received grants of, or was a speaker for, Bristol-Myers Squibb, Eli Lilly, Glaxo Smith Kline, Janssen-Cilag, Lundbeck, Novartis, Nycomed, Organon, Pfizer, and Sanofi-Aventis. *Percentage of Patients on Olanzapine and Ziprasidone With Clinically Significant Metabolic Symptoms at 8 wk. SPSS 14.0 was used for the statistical analysis.A total of 81 patients were screened for eligibility, of whom 74 were randomized to either the ziprasidone arm (Baseline Characteristics of All Randomized Patients (Baseline Characteristics of All Randomized Patients (Baseline Characteristics of All Randomized Patients (Baseline Characteristics of All Randomized Patients (Patient Disposition and Reasons for Discontinuation.Patient Disposition and Reasons for Discontinuation.Positive and Negative Symptom Scale for Schizophrenia.Positive and Negative Symptom Scale for Schizophrenia.Table only includes those adverse events that occurred at statistically different proportions in the 2 groups or in at least 10% of one of the groups.Table only includes those adverse events that occurred at statistically different proportions in the 2 groups or in at least 10% of one of the groups.The percentages of patients who reported adverse events and required concomitant drugs are shown in The analyses revealed significant differences between the 2 study groups in terms of metabolic risk (Percentage of Patients on Olanzapine and Ziprasidone With Clinically Significant Metabolic Symptoms at 8 wk. The results from the PANSS were also considered in terms of proposed remission criteria (“mild” or less on items P1, P2, P3, N1, N4, N6, G5, G9). First, previous use of antipsychotics, comorbidity, or ageing may confound outcome variables such as metabolic effects. Day 1-4: approx. Hypercholesterolemia > 5.17 mmol/l. Combining ziprasidone and olanzapine at the outset of schizophrenia treatment is better than switching from olanzapine to ziprasidone for lessening psychotic symptoms, decreasing movement side effects, and avoiding increased risk of metabolic syndrome, a new study says. In order to gain more insight into the clinical consequences of the study intervention, we performed additional analyses on proportions of patients with All statistical tests were 2 tailed (superiority design), with a 5% level of significance. The study protocol was approved by the local ethical committee and was carried out in accordance with the Declaration of Helsinki.Following the screening period of <10 days, patients were tapered off their psychotropic treatment. Elevated SGOT (>40 U/l). Olanzapine has a profile of good efficacy but with a risk of considerable weight gain.So far, 4 head-to-head RCTs comparing ziprasidone and olanzapine have been published.